Hemab Therapeutics Holdings, Inc.
COAG · Nasdaq · USD · Market cap $1.9B · 59 employees
Hemab Therapeutics Holdings, Inc.
FAIL · Does not pass the screenPrice as of 20 Nov 2026Daily close, not a live quote
Screened 2026-11-20 · the tape above runs as of 14:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price39.29 USD at the 20 Nov 2026 close
- Our value readUndervalued vs our fair value, as of 20 Nov 2026
- Our regime readMarkup, as of 15 Nov 2026
- Ethical screenDoes not pass
- Last reviewed20 Nov 2026 (1 day ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: $54.00 to $70.00, base estimate $64.00 (screen dated 2026-11-20).
- Trend Markup
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options no verdict drawn today, left as found
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its markup label.
Hemab Therapeutics Holdings, Inc. holds its Markup at $39.29. The statistical read favours the buyers, held for 1 days.
| Phase | Markup |
| Quantitative state | The statistical read favours the buyers, held for 1 days |
| Price at the screen | $39.29 |
| Valuation | N/A trailing · -15.04 forward price to earnings |
| Values screen | FAIL · score 70.0 |
Five Screens: COAG's Results
FAIL. Interest-bearing securities
| Test | Figure | Limit | Status |
|---|---|---|---|
| Business activity | Permissible | Permissible core business | Pass |
| Debt load | 0.63% | Below 33% | Pass |
| Interest-bearing cash | 50.06% | Below 33% | Fail |
| Receivables | 46.51% | Below 49% | Pass |
Definitions, sources and threshold rules: ticker values-screen methodology.
The Ethical ReadWhy It Falls Short, in Plain English
Hemab Therapeutics Holdings,'s business is fine, but its cash and interest-bearing securities are about 50% of its assets, well over the ~33% line, so it does not pass on the financial screens.
Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.
Follow this verdict
Get an email when COAG's ethical verdict changes
Today COAG does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads Undervalued to fair value, as of 20 Nov 2026: it trades at roughly a 39% discount to our $64.00 fair value.
USD, 2026-11-20 screen. A 38.6% under base.
Street: 7 covering, consensus Strong Buy. Average target +63%.
Early stage biotech with almost no safety margin
A patient with a rare clotting disorder waits for a new therapy that might never reach the clinic. Hemab is still at that early point, burning cash with zero profit margin and a forward multiple that sits deep in negative territory. The shares trade right at our calculated value, leaving no real buffer if trials slip.
We pass because the ethical screen returns insufficient data and the business offers no proven moat or earnings visibility. Analyst targets cluster at the current price, which simply confirms the market already prices in modest success without rewarding extra risk.
High failure rates in coagulation drug development, repeated dilution, and the complete absence of financial ratios all point to an incomplete picture rather than a compelling opportunity. Analysis, not advice.
| Forward P/E | -15.0x |
| EPS, trailing | -3.55 |
| EPS, forward | -2.65 |
| Profit margin | 0.0%currently unprofitable |
| Debt to equity | 0.23minimal debt: a conservative balance sheet |
| Current ratio | 33.86comfortably covers its short-term bills |
| 52-week range | 23.00 - 55.42 |
| Market cap | $1.9B |
| Employees | 59 |
COAG-specific watchpoints · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Metric definitions and interpretation rules: ticker-page methodology.
Every Entry, As Written
The framework has shifted from accumulation to markup since the last review.
The framework has shifted from markup to accumulation since the last review.
Earnings landed in this window.
The framework has shifted from distribution to markup since the last review.
The framework has shifted from markdown to distribution since the last review. Ethical screening: FAIL.
Written on its date, before the outcome; never pruned.
- Hemab Therapeutics Holdings Inc (COAG) (Q3 2026) Earnings Call Highlights: Pivotal SOLARA Trial ... Yahoo Finance · 10d ago
- Hemab Therapeutics to Participate in Upcoming Investor Conferences Yahoo Finance · 10d ago
- Hemab (COAG) Q3 2026 Earnings Call Transcript Yahoo Finance · 11d ago
- What Hemab Therapeutics (COAG) Said on Its Q3 Earnings Call Yahoo Finance · 11d ago
- Hemab Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update Yahoo Finance · 11d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $25.00 | -0.1% | · | $999 | -0.1% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever COAG does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.